CIC-C1q ELISA is FDA 510(k) cleared. For in vitro Diagnostic Use.
Circulating Immune Complexes
CICs are formed by the interaction of antibodies with immunogenic antigens. Immune complexes with only a slight excess of antibody and antigen are soluble and activate complement. CIC formation may be viewed as a host defence mechanism when directed against foreign antigens. Under normal circumstances CICs are cleared by phagocytosis. If CICs escape phagocytotic clearance they may be deposited in endothelial or vascular structures, thus, provoking an inflammatory response leading to tissue damage. CICs have been associated with an increasing variety of diseases, such as autoimmune, rheumatic, infectious, metabolic, renal, hematological and neoplastic diseases. The CIC-C1q ELISA by BÜHLMANN offers clinicians and researchers a tool that provides useful clinical information regarding immunopathology, prognosis, and follow-up of rheumatic and autoimmune disorders.
|Method||ELISA (96 wells)|
|Time to result||2 h|
|Sample type||20 µl serum or plasma (1:50)|
|Standard range||1-50 µg Eq/ml|
|Sensitivity||< 1 µg Eq/ml
|Catalog Number||see below|
|Status||FDA 510(k) cleared, IVD|